September 18, 2017 — Corindus Vascular Robotics Inc. announced first patient enrollment in the PRECISION GRX Registry, a post-market study to continue market surveillance of the company's second-generation CorPath GRX System.
The PRECISION GRX Registry will include up to 25 sites and enroll up to 1,000 patients receiving robotic-assisted percutaneous coronary intervention (PCI). The study will gather data to evaluate patient outcomes, potential economic benefits, procedural parameters and the expanding capabilities of robotics in PCI. Additional sub-studies will seek to evaluate the impact of robotics on left transradial access and robotic wiring times. Ehtisham Mahmud, M.D., division chief of UC San Diego Health, cardiovascular medicine and medical director, Sulpizio Cardiovascular Center, has been named as the global principal investigator for the PRECISION GRX Study.
"We have shown that robotic-assisted PCI can be used with high clinical and technical success in multiple sites with multiple operators, and the new registry is designed to evaluate the impact of the expanding capabilities of robotics," said Mahmud. "I look forward to spearheading the effort in evaluating this new technology and its value in current practice."
The procedure on the first patient in the trial was performed by Srini Potluri, M.D., at The Heart Hospital Baylor Plano, one of two Baylor hospitals participating in the Registry. The hospital currently has two CorPath GRX Systems installed in its catheterization labs. Potluri stated, "I am excited to participate in the PRECISION GRX Registry to expand the depth of clinical research supporting robotic-assisted PCI. Our participation emphasizes our continuous commitment to advancing patient care in interventional medicine."
For more information: www.corindus.com
May 13, 2026 
